AAPL   321.44 (+1.05%)
MSFT   182.42 (+0.33%)
FB   229.57 (+0.19%)
GOOGL   1,432.17 (+0.84%)
AMZN   2,422.84 (+0.52%)
NVDA   347.14 (+1.80%)
BABA   200.25 (-0.46%)
GE   7.08 (-2.88%)
TSLA   818.12 (-0.26%)
AMD   53.36 (+1.18%)
T   31.51 (-1.10%)
ACB   16.37 (+6.99%)
DIS   118.72 (-2.31%)
NFLX   421.09 (+0.29%)
BAC   25.23 (-2.89%)
BA   154.53 (+3.35%)
AAPL   321.44 (+1.05%)
MSFT   182.42 (+0.33%)
FB   229.57 (+0.19%)
GOOGL   1,432.17 (+0.84%)
AMZN   2,422.84 (+0.52%)
NVDA   347.14 (+1.80%)
BABA   200.25 (-0.46%)
GE   7.08 (-2.88%)
TSLA   818.12 (-0.26%)
AMD   53.36 (+1.18%)
T   31.51 (-1.10%)
ACB   16.37 (+6.99%)
DIS   118.72 (-2.31%)
NFLX   421.09 (+0.29%)
BAC   25.23 (-2.89%)
BA   154.53 (+3.35%)
AAPL   321.44 (+1.05%)
MSFT   182.42 (+0.33%)
FB   229.57 (+0.19%)
GOOGL   1,432.17 (+0.84%)
AMZN   2,422.84 (+0.52%)
NVDA   347.14 (+1.80%)
BABA   200.25 (-0.46%)
GE   7.08 (-2.88%)
TSLA   818.12 (-0.26%)
AMD   53.36 (+1.18%)
T   31.51 (-1.10%)
ACB   16.37 (+6.99%)
DIS   118.72 (-2.31%)
NFLX   421.09 (+0.29%)
BAC   25.23 (-2.89%)
BA   154.53 (+3.35%)
AAPL   321.44 (+1.05%)
MSFT   182.42 (+0.33%)
FB   229.57 (+0.19%)
GOOGL   1,432.17 (+0.84%)
AMZN   2,422.84 (+0.52%)
NVDA   347.14 (+1.80%)
BABA   200.25 (-0.46%)
GE   7.08 (-2.88%)
TSLA   818.12 (-0.26%)
AMD   53.36 (+1.18%)
T   31.51 (-1.10%)
ACB   16.37 (+6.99%)
DIS   118.72 (-2.31%)
NFLX   421.09 (+0.29%)
BAC   25.23 (-2.89%)
BA   154.53 (+3.35%)
Log in

ASX:BNOBionomics Stock Price, Forecast & News

A$0.04
0.00 (0.00 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$0.04
Now: A$0.04
A$0.05
50-Day Range
A$0.04
MA: A$0.05
A$0.06
52-Week Range
A$0.03
Now: A$0.04
A$0.15
Volume386,458 shs
Average Volume795,392 shs
Market Capitalization$23.42 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company's product pipeline includes BNC210, a negative allosteric modulator, which is in Phase II clinical trial for the treatment of generalized anxiety disorder, as well as is in Phase II clinical trial in patients with post-traumatic stress disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a vascular disrupting agent for the treatment of cancer, as well as disrupts the blood vessels that nourish tumors in cancer treatment. It also offers Multicore, a suite of integrated synthetic methods that gives access to complex drug-like molecules; and ionX, an integrated platform of genomics discoveries and technologies that serves as the foundation for Bionomics' CNS drug discovery and development, as well as contract research services. The company has a collaborative partnership with Merck & Co., Inc. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.63 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+61-8-83546100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.15 million
Cash FlowA$0.02 per share
Book ValueA$0.02 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$23.42 million
Next Earnings DateN/A
OptionableOptionable

Receive BNO News and Ratings via Email

Sign-up to receive the latest news and ratings for BNO and its competitors with MarketBeat's FREE daily newsletter.

Bionomics (ASX:BNO) Frequently Asked Questions

How has Bionomics' stock been impacted by COVID-19 (Coronavirus)?

Bionomics' stock was trading at A$0.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BNO shares have decreased by 8.5% and is now trading at A$0.04. View which stocks have been most impacted by Coronavirus.

How were Bionomics' earnings last quarter?

Bionomics Ltd (ASX:BNO) posted its quarterly earnings results on Friday, February, 15th. The company reported ($0.02) earnings per share (EPS) for the quarter. View Bionomics' earnings history.

Has Bionomics been receiving favorable news coverage?

News stories about BNO stock have trended somewhat negative on Thursday, according to InfoTrie. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Bionomics earned a daily sentiment score of -1.7 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutBionomics.

Who are some of Bionomics' key competitors?

What other stocks do shareholders of Bionomics own?

Who are Bionomics' key executives?

Bionomics' management team includes the following people:
  • Dr. Errol B. De Souza, Exec. Chairman (Age 66)
  • Mr. Jack Moschakis BEc, DipLaw(BAB), GDipBA, FCIS, Legal Counsel & Company Sec.
  • Prof. Paul Rolan, Consultant Medical Officer of Clinical Neuroscience

What is Bionomics' stock symbol?

Bionomics trades on the ASX under the ticker symbol "BNO."

What is Bionomics' stock price today?

One share of BNO stock can currently be purchased for approximately A$0.04.

How big of a company is Bionomics?

Bionomics has a market capitalization of $23.42 million and generates $10.15 million in revenue each year.

What is Bionomics' official website?

The official website for Bionomics is www.bionomics.com.au.

How can I contact Bionomics?

Bionomics' mailing address is 31 Dalgleish St, THEBARTON, SA 5031, Australia. The company can be reached via phone at +61-8-83546100.

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.